Caprelsa 300mg is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Vandetanib is a generic form of brand name Caprelsa 300mg which is a prescription medication required to treat patients with medullary thyroid cancer (MTC) which cannot be taken out by surgery or that has spread to other parts of the body, and in which the tumor are developing or causing symptoms. This type of medullary thyroid cancer is usually called advanced medullary thyroid cancer (aMTC).
In which the drug takes a long time to get eradicate of Caprelsa 100mgfrom your body and you may be at risk for adverse reaction related to Caprelsa 100mgafter you have stopped your treatment.
Mechanism of action
Caprelsa 300mg is a type which belongs to kinase inhibitor. A kinase is a kind of enzyme which can indicate other molecules in a cell, contain a cancer cell, to form active. Caprelsa 300mg prohibits the cell communication and may inhibits tumor growth. It's also important to note that regular cells can be affected by your treatment with Caprelsa 100mg, which could cause in side effects.
Time to peak plasma concentration is 6 hr (range 4-10 hr) and steady state is 3 months
Bounding of plasma protein is 90% and volume of distribution is 7450L
Caprelsa 300mg is metabolized by CYP3A4
The drug elimination through feces 44% and via urine collection period of 21 day after single dose.
The recommended dose of Caprelsa is 300mg administrated orally once daily until disease progression or unacceptable toxicity occurs
Avoid crushing of tablets, disperse the tablet in 2 ounces of water by stirring 10 minutes approximately. Be careful, do not use other liquids for dispersion and swallow the medicine soon after dispersion, if any remaining residue with 4 additional ounces of water and swallow.
Th dispersion liquid can be administrated via nasogastric or gastrostomy tubes.
Headache, Fatigue, Low blood sugar, Abdominal pain, Poor appetite, Low white blood cell count, Kidney problems, Dry skin, Vomiting, Weakness, Irregular heart beat, Insomnia (difficulty sleeping), Photosensitivity (sensitivity to sunlight), Bleeding, Anemia, Liver tests increased (bilirubin), Itching, Heartburn, Cough, Upper respiratory infection, Depression, Weight loss, Diarrhea, Rash, Elevated Liver Enzymes (ALT), Low calcium levels, Acne, High blood pressure, Nausea.
Effective CYP3A4 inducers decreased exposure to Vandetanib by up to 40%; however, no clinically significant effect on exposure to Vandetanib was observed in the presence of the potent CYP3A4 inhibitors.
Fatal skin reactions, containing Stevens-Johnson syndrome and serious toxic epidermal necrolysis resulted; systemic treatment such as corticosteroids may be needed; permanently stop therapy for severe skin reactions.
Interstitial lung disease (ILD), causes in death has been reported; interfere withVandetanib and examine unexplained Dyspnea, cough, and fever; applicable measures should be taken for ILD
Ischemic cerebrovascular events, haemorrhage, heart failure, diarrhea, hypothyroidism, hypertension, and reversible posterior leukoencephalopathy syndrome, have been observed
Can cause risk of fetal when administered to pregnant women; Do not get pregnancy while gettingVandetanib and for 4 months following treatment